Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.msard.2020.102402 http://scihub22266oqcxt.onion/10.1016/j.msard.2020.102402 32711297!7366111!32711297     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32711297&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Mult+Scler+Relat+Disord 2020 ; 45 (?): 102402 Nephropedia Template TP {{tp|p=32711297|t=2020. COVID-19 and multiple sclerosis: A description of two cases on alemtuzumab |pdf=|usr=}}{{32711297}} gab.com Text COVID-19 and multiple sclerosis: A description of two cases on alemtuzumab JO: Mult Scler Relat Disord http://www.kidney.de/pget.php?&tw=1&pmid=32711297 #FOAvip BACKGROUND: Alemtuzumab is a treatment for highly active multiple sclerosis (MS). Immunosuppression is considered a risk factor for SARS-CoV-2 infection and there is still lack of evidence to guide MS practice. METHODS/RESULTS: We describe the clinical and immunological evolution of two MS patients under alemtuzumab treatment who were affected by COVID-19, one of them only one week after receiving her last dose, and both recovered without sequelae. CONCLUSION: In selected patients (young, without comorbidities, and with high activity), MS itself could be more dangerous than COVID-19, so we should consider continuing MS treatment as previously planned, including alemtuzumab. Twit Text FOAVip COVID-19 and multiple sclerosis: A description of two cases on alemtuzumab ????Mult Scler Relat Disord http://www.kidney.de/pget.php?&tw=1&pmid=32711297 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32711297 #FOAvip English Wikipedia <ref>{{Cite pmid|32711297}}</ref> COVID-19 and multiple sclerosis: A description of two cases on alemtuzumab #MMPMID32711297 Fernandez-Diaz E; Gracia-Gil J; Garcia-Garcia JG; Palao M; Romero-Sanchez CM; Segura T Mult Scler Relat Disord 2020[Oct]; 45 (?): 102402 PMID32711297show ga BACKGROUND: Alemtuzumab is a treatment for highly active multiple sclerosis (MS). Immunosuppression is considered a risk factor for SARS-CoV-2 infection and there is still lack of evidence to guide MS practice. METHODS/RESULTS: We describe the clinical and immunological evolution of two MS patients under alemtuzumab treatment who were affected by COVID-19, one of them only one week after receiving her last dose, and both recovered without sequelae. CONCLUSION: In selected patients (young, without comorbidities, and with high activity), MS itself could be more dangerous than COVID-19, so we should consider continuing MS treatment as previously planned, including alemtuzumab. |*Immunocompromised Host[MESH] |Adult[MESH] |Alemtuzumab/*therapeutic use[MESH] |Antineoplastic Agents, Immunological/*therapeutic use[MESH] |Betacoronavirus[MESH] |COVID-19[MESH] |Coronavirus Infections/*immunology[MESH] |Female[MESH] |Humans[MESH] |Male[MESH] |Multiple Sclerosis, Relapsing-Remitting/*drug therapy/*virology[MESH] |Pandemics[MESH] |Pneumonia, Viral/*immunology[MESH]COVID-19 and multiple sclerosis: A description of two cases on alemtuz(epmc).pdf DeepDyve Pubget Overpricing